Barnes Group Inc. - B STOCK NEWS

Nearmap, a global leader in location intelligence solutions, has announced the expansion of its imagery coverage across the U.S. through a partnership with Hexagon's Content Program. This addition complements Nearmap's existing coverage of 87% of the U.S. population, allowing insurers to gain insights into less populated geographic regions.

The expanded coverage will be accessible through Partner Connect, the Betterview platform's ecosystem for integrating third-party geospatial datasets and tools. This enhancement enables insurance companies to:

• Optimize underwriting efficiency
• Reduce physical inspection spending
• Recommend risk mitigation steps to policyholders

Nearmap surveys over 100 million parcels in the United States up to three times per year, providing insurance companies with valuable location insights for better-informed decisions across the entire policy lifecycle.

ETQ, part of Hexagon, has launched the ETQ Reliance® Predictive Quality Analytics solution, integrating AI-driven analytics into its quality management system (QMS). This solution, developed in partnership with Acerta Analytics, enables automated early detection and proactive resolution of manufacturing issues.

Key features include:

• Manufacturing-specific data ingestion
• Advanced data analysis
• Predictive monitoring and alerts
• Automated root cause analysis

The solution aims to prevent production problems, limit variation, speed decision-making, and improve overall quality. It combines Acerta's LinePulse AI and machine learning technology with ETQ Reliance's advanced quality workflows, creating a predictive, closed-loop quality system.

This launch addresses manufacturers' concerns about plant performance, operational efficiency, compliance, risk management, and product recalls. The solution is available immediately for both new and existing ETQ Reliance NXG customers.

Barnes Group Inc. (NYSE: B) has announced an agreement to be acquired by funds managed by affiliates of Apollo Global Management, Inc. (NYSE: APO) in an all-cash transaction valued at approximately $3.6 billion. Barnes shareholders will receive $47.50 per share in cash, representing a premium of about 22% over Barnes' undisturbed closing share price on June 25, 2024.

The transaction, expected to close before the end of Q1 2025, is subject to approval by Barnes shareholders and regulatory approvals. Upon completion, Barnes will become a privately held company but continue to operate under the Barnes Group name and brand. The Barnes Board of Directors unanimously approved the agreement and recommends shareholders vote in favor.

As a result of this pending transaction, Barnes has suspended its financial guidance for the full year 2024 and will not conduct its third quarter 2024 conference call and webcast.

Fortunafi has announced the tokenization of Hilbert Capital's V1 Fund on Coinbase's Base, an Ethereum Layer-2 blockchain. Hilbert Capital, the asset management division of Nasdaq-listed Hilbert Group AB (NASDAQ: HILB B), joins Fortunafi's Tokenized Asset Protocol (TAP) app. The Hilbert V1 Fund aims to deliver absolute returns through an algorithmic market-neutral strategy, leveraging cryptoasset market properties for superior risk-adjusted returns.

Hilbert Capital, established in 2017, has a 7-year strategy performance track record and a team of 16 investment professionals, including 4 quantitative PhDs. This partnership is expected to expand Reservoir's reach and provide a new way of sourcing assets for Hilbert, while generating yield for Fortunafi's protocol users. The collaboration is seen as mutually beneficial, combining Fortunafi's crypto expertise with Hilbert's trading operation.

Barnes Group Inc. (NYSE: B) has announced its third quarter 2024 earnings conference call and webcast, scheduled for Friday, October 25, 2024. The company will release its financial results before the market opens and host a conference call at 8:30 a.m. (ET) to discuss the results and outlook. Investors can access the call through a live audio webcast on Barnes' website or via direct dial. The call will be recorded and available for playback until November 1, 2024. Supplemental materials will be posted on the company's Investor Relations section prior to the conference call.

BioArctic AB (Nasdaq Stockholm: BIOA B) has announced the publication of results from two phase 1 studies of exidavnemab in The Journal of Clinical Pharmacology. Exidavnemab is a monoclonal antibody targeting aggregated forms of α-synuclein, aimed at treating diseases like Parkinson's disease. The studies, conducted with AbbVie, involved 98 healthy volunteers, with 85 receiving exidavnemab. Results showed that exidavnemab was generally well-tolerated with an excellent half-life of approximately 30 days. The drug's high affinity and selectivity toward pathological α-synuclein aggregates are key for maintaining high target binding in the brain. CEO Gunilla Osswald expressed anticipation for starting the phase 2a study later this year.

Guidehouse, a global consultancy, has partnered with Hexagon, a digital reality solutions leader, to drive innovation in the public sector. This collaboration aims to enhance operational efficiency, transparency, and performance of government agencies throughout their assets' lifecycle. Key benefits include:

• Enhanced operational efficiency and data-driven decision-making
• Improved transparency and accountability in asset management
• Modernized solutions for mission-critical needs and lifecycle cost management
• Optimized lifecycle asset performance

The partnership combines Hexagon's cutting-edge technology with Guidehouse's public-sector expertise to deliver comprehensive solutions for complex government challenges, from asset acquisition and deployment to maintenance and decommissioning.

BioArctic AB announced that its partner Eisai received Marketing Authorization from the MHRA in Great Britain for Leqembi (lecanemab) to treat mild cognitive impairment and mild dementia due to Alzheimer's disease in specific adult patients. This marks the first authorization in Europe for a medicine targeting an underlying cause of Alzheimer's disease.

Lecanemab selectively binds to and clears toxic Aβ protofibrils from the brain. The approval was based on the Phase 3 Clarity AD clinical trial, which met its primary and key secondary endpoints. Common adverse reactions include infusion-related reactions and amyloid-related imaging abnormalities.

Eisai is working with health authorities to make Leqembi available to eligible patients. The antibody was originally developed by BioArctic, resulting from a collaboration with Eisai.

BioArctic AB (NASDAQ Stockholm: BIOA B) has addressed recent rumors circulating in British media regarding the imminent approval of lecanemab in Great Britain. The company stated that it has not been informed of any decision made by the relevant authorities and is therefore unable to comment on these speculations. BioArctic has committed to updating the market if new information becomes available. This statement was released for public disclosure on August 22, 2024, at 08:34 a.m. CET. The company has provided contact information for its VP of Communications and IR, Oskar Bosson, for further inquiries.